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Eucalyptus globulus Labill. decoction extract
inhibits the growth of NCI-H460 cells by
increasing the p53 levels and altering the cell
cycle profile
Alexandra Teixeira, †a,b Déborah C. DaCunha, †a,b Lillian Barros, c
Hugo R. Caires, *a,b Cristina P. R. Xavier, *a,b Isabel C. F. R. Ferreira c and
M. Helena Vasconcelos a,b,d
Eucalyptus globulus Labill. is a widespread evergreen plant belonging to the Myrtaceae family. Several
species of Eucalyptus are known to have a plethora of medicinal properties, particularly anti-tumor
activity, which prompts the study of the chemical composition and bioactivity of extracts from this plant.
Hereby, the main aims of this work were to (i) profile the phenolic compounds in E. globulus extracts pre-
pared by decoction and infusion; (ii) test the cell growth inhibitory activity of E. globulus decoction and
infusion, in three human tumor cell line models: colorectal, pancreatic and non-small cell lung cancer
(HCT-15, PANC-1 and NCI-H460, respectively); and (iii) study the mechanism of action of the most
potent extract in the most sensitive cell line. Our work demonstrated that both the decoction and infusion
preparations revealed the presence of phenolic acids, flavonoids and gallotannins, the last group being
the most abundant polyphenols found, especially two digalloyl-glucosides. Both extracts inhibited the
growth of all the tumor cell lines tested. The decoction extract was the most potent in inhibiting the
NCI-H460 cell growth (lower GI50 determined by sulforhodamine B assay), which could be due to its
higher content of phenolic compounds. Hence, the effect of the decoction extract on the NCI-H460
cells was further investigated. For this, cell viability (by Trypan blue exclusion assay), the cell cycle profile
and apoptosis (by flow cytometry), cell proliferation (by bromodeoxyuridine assay) and protein expression
(by western blot) were analyzed. Two different concentrations of the extract (52 μg mL−1 and 104
μg mL−1, corresponding to GI50 and 2 × GI50 concentration) were tested in these studies. Remarkably,
the E. globulus decoction extract caused a dose-dependent decrease in the NCI-H460 cell number,
which was correlated with a cell cycle arrest in the G0/G1 phase, a decrease in cell proliferation and an
increase in the expression of p53, p21 and cyclin D1 proteins. Interestingly, no differences were found in
the levels of ds-DNA damage and in the levels of apoptosis. This work highlights the relevance of the
Eucalyptus globulus Labill. extract as a source of bioactive compounds with potential anti-tumor activity.
Introduction
Plant extracts have been widely used as a natural source of
medicinal compounds for the treatment of several diseases,1–3
including cancer.4–6 Cancer has become a global public health
problem with an urgent need for novel anti-neoplastic drugs
and therapeutic approaches. Given this problematic issue, the
screening of natural compounds as potential anti-tumor
agents has become an interesting approach worldwide.7–12
Most notably, nearly half of the small molecules approved for
cancer treatment were either actually natural products or
derived from such products.13 Some of the most relevant anti-
cancer drugs in this category include frequently used agents
such as Taxol, vinblastine and camptothecin.14–16†These authors equally contributed to the work.
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Eucalyptus globulus Labill. is one of the most widespread
evergreen trees, or shrubs, native to Australia and Tasmania
regions. Eucalyptus belongs to the Myrtaceae family and nowa-
days it has extensively spread to various countries.17 This plant
has been the object of several studies due to its pronounced
potential for several medicinal and pharmacological appli-
cations. In addition, Eucalyptus’ extracts and their essential
oils are also currently used in cosmetics and as food additives.
Indeed, some of the Eucalyptus constituents, such as alkaloids,
polyphenols and propanoids display anti-cancer, anti-
inflammatory, anti-fungal, anti-bacterial and anti-septic
properties.18–22 For example, Eucalyptus sideroxylon and
Eucalyptus torquata oils and extracts of leaves, stems, and
flowers were demonstrated to have anti-microbial and cytotoxic
activities in human hepatocellular carcinoma (HEPG2) and in
breast adenocarcinoma (MCF7) cell lines.23 Moreover, com-
pounds isolated from the leaves of Eucalyptus cinerea also
showed activity against MCF7, HEP2 (laryngeal carcinoma),
and CaCo (colonic adenocarcinoma) cell lines, suggesting a
wider use of Eucalyptus species for pharmaceutical purposes.24
Furthermore, regarding specifically the Eucalyptus globulus
Labill. extract, a recent study has shown a promising cytotoxic
effect of some phloroglucinol derivatives, isolated from the fruits
of this species, in A549 (human lung cancer), 4 T1 (murine
breast cancer), and B16F10 (murine myeloma) cell lines.25
Therefore, the present study aimed to test the potential
anti-cancer cell growth inhibitory effect of Eucalyptus globulus
Labill. aqueous extracts, prepared by infusion and decoction,
in three human tumor cell lines: the human colorectal adeno-
carcinoma HCT-15, the exocrine pancreatic cancer PANC-1 and
the non-small cell lung cancer NCI-H460. Importantly, the
effect of the decoction extract of E. globulus was further ana-
lyzed on the most sensitive cell line (NCI-H460), particularly
on cell apoptosis, the cell cycle profile and cell proliferation.
Ultimately, the phenolic profile of both aqueous extracts was
also tested in order to corroborate the obtained data.
Materials and methods
Samples and extract preparations
Eucalyptus globulus Labill. fresh aerial parts were collected ran-
domly, from growing plants in the campus of the Polytechnic
Institute of Bragança (Northern Portugal) in June 2016. The
collected biomass was separated, cleaned and lyophilized
(−49 °C and 0.041 bar, FreeZone 4.5, Labconco, Kansas City,
MO, USA). The dried plants were ground to a fine powder
(∼20 mesh) and stored at 4 °C for further analyses. Decoctions
were prepared using 1 g of plant material mixed with 200 mL
of distilled water and then allowed to boil. Afterwards, they
were left to boil for an additional 5 min in a closed flask,
allowed to stand at room temperature for an additional 5 min
and then filtered under reduced pressure. Infusions were pre-
pared using 1 g of the plant material with 200 mL of distilled
boiling water (100 °C), allowed to infuse for 5 min at room
temperature, and then filtered through Whatman no. 4 paper.
Both aqueous extracts were then further frozen (−20 °C) and
lyophilized to obtain a dry extract. The lyophilized products
were then dissolved in water and a stock solution at 25
mg mL−1 was prepared and stored at −20 °C.
Phenolic compound characterization by LC-DAD-ESI/MS
The phenolic compounds were determined by HPLC-DAD-ESI/
MSn (Dionex Ultimate 3000, Thermo Finnigan, San Jose, CA,
USA), following a methodology previously described by the
authors.26 The aqueous extracts were analyzed at a concen-
tration of 5 mg mL−1, and the compounds were detected using
a diode array detector (DAD, recording at 280, 330 and
370 nm), and a Linear Ion Trap LTQ XL mass spectrometer
(Thermo Finnigan, San Jose, CA, USA), operating in negative
mode. Identification was performed by comparing retention
times (RT) and mass spectrum fragments with literature
reported data or by comparison with commercially available
standards (Extrasynthese, Genay, France). Quantification was
made on the basis of the UV-vis signal of each available pheno-
lic standard, where calibration curves were obtained by inject-
ing known concentrations (2.5–100 μg mL−1). The results were
processed using the Xcalibur®data system and expressed in
mg per g of extract.
Cell culture
Three different human tumor cell lines were studied: PANC-1
(exocrine pancreatic carcinoma), NCI-H460 (non-small cell
lung cancer) and HCT-15 (colorectal adenocarcinoma). All the
cell lines were maintained in RPMI-1640 medium with
Ultraglutamine I and 25 mM 4-(2-hydroxyethyl) piperazine-1-
ethanesulfonic acid, HEPES (Lonza, Basel, Switzerland). This
medium was supplemented with 5% fetal bovine serum, FBS
(Biowest Nuaillé, France), for the cell growth inhibition assay
(sulforhodamine B assay) or with 10% FBS for the remaining
experiments. The adherent cells were kept at 37 °C in a
humidified incubator containing 5% CO2. Routinely, cells were
observed using an inverted light microscope (Leica DMi1). The
cell number and viability were assessed by cell counting with
an hemocytometer using the Trypan blue exclusion assay
(Trypan Blue reagent – Sigma-Aldrich, St Louis, MO, USA). All
the experiments were carried out with cells at the exponential
phase of growth and with more than 90% viability.
Cell growth inhibition assay
The sulforhodamine B (SRB) assay was used to assess the cell
growth inhibitory potential of the extracts.27,28 Cells were
plated in 96-well plates at a previously determined optimal
concentration (5.0 × 104 cells per mL for NCI-H460 and
PANC-1 cells and 1.0 × 105 cells per mL for HCT-15 cells). After
24 h incubation, cells were treated with five serial dilutions of
Eucalyptus globulus L. infusion or decoction, ranging from
200 µg mL−1 to 12.5 µg mL−1. Doxorubicin (ranging from
2000 nM to 125 nM for HCT-15 cells and from 100 nM to
6.25 nM for NCI-H460 cells) and gemcitabine (ranging from
5000 to 312.5 nM for PANC-1 cells) were used as positive con-
trols (both from Sigma-Aldrich). The effect of the extracts’
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solvent (water) on the growth of the cells was also evaluated,
by treating cells with the maximum concentration of water
used. In addition, cells were treated with the complete culture
medium only, providing a normal cell growth control. Two
plates were prepared: one to be analyzed immediately (T0) and
another to be analyzed 48 h later (T48). Therefore, following
48 h incubation with treatments for the T48 plate (or immedi-
ately for the T0 plate), cells were fixed by adding ice-cold 10%
trichloroacetic acid (TCA) (w/v, final concentration; Panreac,
Barcelona, Spain), washed with water and then stained with
1% SRB (Sigma Aldrich) in 1% (v/v) acetic acid. The solubil-
ization of the bound dye was done by adding 10 mM Tris base
solution (Sigma-Aldrich). The absorbance was measured at
510 nm using a microplate reader (BioTek® Synergy HT,
Winooski, VT, USA). The GI50 values (concentrations that
inhibited cell growth by 50%) were determined for E. globulus
infusion and decoction extracts in the three cell lines.
Preparation of cells for other analyses
For further analyses of the activity of the extracts – cell cycle
profile, apoptosis, cell proliferation and western blot – the
NCI-H460 cells were plated at 3.3 × 104 cells per mL in 6-well
plates. Following an incubation for 24 h, different treatments
of E. globulus or controls were applied to the cells: 52 µg mL−1
of decoction extract (approximately the GI50 concentration),
104 µg mL−1 of decoction extract (approximately twice the GI50
concentration, 2 × GI50), medium (Blank), water (in a concen-
tration equivalent to the one used in the treatments for GI50
and 2 × GI50 of plant extract, corresponding to Control 1 and
Control 2, respectively) and 17 nM doxorubicin (positive
control). After 48 h of treatment, cells were trypsinized and
centrifuged at 290g for 5 min (including medium and
detached dead cells). Of note, after trypsinization the cells
from each well were collected and counted, using the Trypan
blue exclusion assay and the percentage of the viable cell
number was determined. Cells were then handled according to
the procedures described in the next sections.
Analysis of the cell cycle profile
After the procedure stated above, cells were fixed with ice-cold
70% ethanol and stored at 4 °C for at least 12 h. Cells were
then centrifuged at 290g for 5 min and pellets were resus-
pended in a phosphate-buffered saline solution, PBS, contain-
ing 0.1 mg mL−1 RNase A and 5 µg mL−1 propidium iodide
(PI) (Sigma-Aldrich). The cellular DNA content was analyzed by
flow cytometry. The percentage of cells in the G0/G1, S and
G2/M phases of the cell cycle was determined using the BD
Accuri™ C6 Flow cytometer (BD Biosciences), after proper
exclusion of cell debris and aggregates, and plotting at least
20 000 events per sample.29–31 Data were analyzed using the
FlowJo software (version 7.6.5, Tree Star, Inc., Ashland, OR,
USA).
Analysis of apoptosis
Following centrifugation, cells were resuspended in buffer
solution from the Annexin V-FITC Apoptosis Detection Kit
(eBioscience™), as indicated by the manufacturer’s instruc-
tions. Then, cells were incubated with Human Annexin V-FICT
for 10 min on ice, protected from light. After the addition of
PI, cells were immediately analyzed by flow cytometry using
the BD Accuri™ C6 Flow cytometer and its corresponding soft-
ware, plotting at least 10 000 events per sample.30,31 The auto-
fluorescence of each sample and of the Annexin and PI was
also measured, in order to make proper fluorescence
compensation.
Analysis of protein expression
Cell pellets were washed with PBS (200g, 5 min) and then lysed
in Winman’s buffer (1% NP-40, 0.1 M Tris-HCl pH 8.0, 0.15 M
NaCl and 5 mM EDTA), complemented with protease inhibitor
cocktail (Roche, Basel, Switzerland). The total protein content
was quantified using the DC™ Protein Assay kit (Bio-Rad,
Hercules, CA, USA), following the manufacturer’s instructions.
Protein lysates corresponding to each treatment were loaded
(in equal amounts) on 12% SDS-PAGE gel and transferred into
a nitrocellulose membrane (Amersham Protran 0.45 NC, GE
Healthcare, Buckinghamshire, UK). After blocking with 5%
(w/v) non-fat dry milk (Molico), membranes were incubated
with the following primary antibodies: rabbit anti-PARP-1
(1 : 2000; sc-7150, Santa Cruz Biotechnology, Heidelberg,
Germany), mouse anti-p53 (1 : 5000; sc-126, Santa Cruz
Biotechnology), mouse anti-p21 (1 : 250; OP64, Calbiochem,
San Diego, CA, USA), rabbit anti-γ-H2A·X (1 : 200; sc-101696,
Santa Cruz Biotechnology), mouse anti-Cyclin D1 (1 : 400; sc-
8396, Santa Cruz Biotechnology) and goat anti-Actin (1 : 2000,
sc-1616, Santa Cruz Biotechnology). The corresponding sec-
ondary antibodies were goat anti-rabbit IgG-HRP (sc-2004),
goat anti-mouse IgG-HRP (sc-2031) and donkey anti-goat
IgG-HRP (sc-2020) (all at a dilution of 1 : 2000 from Santa Cruz
Biotechnology). For signal detection, the Amersham™ ECL
Western Blotting Detection Reagents (GE Healthcare), the
High Performance Chemiluminescence Film (GE Healthcare)
and the Kodak GBX developer and fixer (Sigma-Aldrich) were
used.32,33 The intensity of the bands was analyzed using the
software Quantity One – ID Analysis (Bio-Rad).
Analysis of cell proliferation
Cell proliferation was assessed using the bromodeoxyuridine
(BrdU) incorporation assay, according to the previously
described protocol.34 Briefly, 3 h before harvesting the cells
(during the 48 h treatment), cells were incubated with 10 µM
BrdU (Sigma-Aldrich). Cells were washed and fixed with 4%
paraformaldehyde, PFA (Panreac) in PBS. After the preparation
of cytospins, cells were treated with 2 M HCl for 20 min (DNA
denaturation). Cells were then incubated with a mouse anti-
BrdU antibody (1 : 10; Dako), followed by the incubation with
anti-mouse-Ig-FITC (1 : 100; Dako). After that, slides were pre-
pared with Vectashield mounting medium containing
4′,6-diamidino-2-phenylindole, DAPI (Vector Laboratories Inc,
Burlingame, CA, USA). The detection of BrdU incorporation
(green nuclei) was possible using a DM2000 microscope
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(LEICA; Wetzlar, Germany) and a semi-quantitative evaluation
was performed by counting a minimum of 500 cells per slide.
Statistical analysis
Experimental data are shown as the mean ± standard error of
the mean (S.E.M.), from at least three independent experi-
ments. Statistical analysis was performed using the two-tailed
paired Student’s t-test. A p value < 0.05 was established to con-
sider statistically significant data.
Results and discussion
Phenolic compound composition in Eucalyptus globulus
Labill. aqueous extracts
The chromatographic characteristics of the tentatively identi-
fied phenolic compounds in E. globulus extracts, prepared by
decoctions and infusions, are presented in Table 1. Eighteen
polyphenols were detected, seven of which were flavonoids
(quercetin, isorhamnetin, and myricetin derivatives), three
phenolic acids (chlorogenic acid and ellagic acid derivatives),
and eight gallotannin derivatives. The identified compounds
in the aqueous extracts were identified taking into account the
previous findings found by some of the authors in a hydro-
methanolic extract of E. globulus.35 Nevertheless, these extracts
did not reveal the presence of the pentagalloyl-glucoside and
presented a slightly lower amount of the identified com-
pounds, probably due to the different solvents and extraction
methodology applied.
Both extracts, decoctions and infusions, revealed a high
concentration of gallotannins, followed by phenolic acids and
flavonoids, respectively. The digalloyl-glucoside (compound 1)
was the main gallotannin present in the decoctions and infu-
sions, with 5-O-caffeoylquinic acid being the second major
compound. The decoctions were the aqueous extracts that
revealed the highest concentration in all the mentioned poly-
phenol groups.
E. globulus extracts inhibited the growth of various human
tumor cell lines
In order to determine the in vitro cytotoxicity of the E. globulus
aqueous extracts in human tumor cell lines, the sulforhoda-
mine B (SRB) assay was performed. The extracts prepared by
infusion and decoction were tested in three different human
tumor cell line models: non-small cell lung cancer (NCI-H460
cell line), colorectal adenocarcinoma (HCT-15 cell line) and
pancreatic ductal adenocarcinoma (PANC-1 cell line). Indeed,
the first two cell line models represent two of the most fre-
quent and fatal types of oncologic malignancies (lung and col-
orectal cancers), while the latter remains as one of the most
lethal types of cancers worldwide.5,36,37
Table 2 and Fig. 1 present the results of the SRB assay,
showing that both extracts have cell growth inhibitory poten-
tial in all the cell lines tested. Doxorubicin and gemcitabine,
two clinically used drugs to treat these types of cancers, were
used as positive controls.
Importantly, the in vitro cytotoxicity screening of E. globulus
extracts in these distinct tumor cell models revealed that
NCI-H460 was the most sensitive cell line, followed by PANC-1
and HCT-15, respectively. Interestingly, we have also observed
enhanced cytotoxic potency of the decoction E. globulus
extracts on the NCI-H460 cell line compared to the infusion
preparation. Indeed, the decoction preparation was the most
potent one, presenting the lowest observed GI50 (51.7 ± 2.0
µg mL−1). This could be related to its higher concentration in
phenolic compounds, particularly in gallotannins (digalloyl-
glucoside, eucaglobulin/globulusin B, trigalloyl-glucoside, and
tetragalloyl-glucose).
Taken together, the observed anti-tumor effect of
E. globulus seems to be heavily reliant on not only the type of
tumor cell line but also the type of extract. In order to under-
stand the putative anti-tumor mechanism of action of the
E. globulus extracts, additional experiments were conducted
using the most potent E. globulus (decoction) preparation, in
the most sensitive (NCI-H460) tumor cell line.
E. globulus decoction extract reduced the NCI-H460 cellular
viability
The effect of two concentrations of the decoction extracts
[52 µg mL−1 and 104 µg mL−1, corresponding to approximately
the GI50 and twice the GI50 (2 × GI50) concentrations, respect-
ively] was studied in the most sensitive cell line (NCI-H460).
Consistently, the E. globulus decoction extract, at both con-
centrations, significantly decreased the number of NCI-H460
viable cells, corroborating the results obtained previously with
the SRB assay. Indeed, the results presented in Fig. 2 show
that treatment with 52 µg mL−1 of E. globulus decoction extract
significantly reduced the percentage of the viable cell number
by 33%, while treatment with a higher concentration (104
µg mL−1) caused a reduction of 62%, when compared to the
number of viable cells in the Blank control (cells without any
treatment). These results confirm that the E. globulus decoc-
tion extract induced a dose-dependent decrease in the
NCI-H460 viable cell number. It is noteworthy that no differ-
ences were found between the Blank control and the
additional negative controls (Controls I and II). Interestingly,
no prominent morphological alterations were noticed on the
cells treated with either concentrations of the extract, when
compared to the controls (images not shown).
E. globulus decoction extract altered the cell cycle profile of
NCI-H460 cells
Given the anti-tumor cell growth inhibitory potential of the
E. globulus decoction extract, we have further investigated
whether this extract is able to influence the NCI-H460 cell
cycle profile. Importantly, we have observed by flow cytometry
that NCI-H460 cells treated with the 2 × GI50 concentration of
the E. globulus decoction extract (104 µg mL−1) had a signifi-
cant increase in the % of cells in the G0/G1 phase, in relation
to the Blank, together with a statistically significant decrease
in the percentage of cells in the S phase (Fig. 3).
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Table 1 Chromatographic characteristics, tentative identification and quantification (mean value ± standard deviation) of the phenolic compounds present in the aqueous extracts of Eucalyptus
globulus Labill
Peak Rt (min) λmax (nm)
Molecular ion




1 5.6 276 483 331(31), 313(27), 271(100), 211(12), 169(5) Digalloyl-glucoside(A) 27.8 ± 0.1 22.9 ± 0.7 <0.001
2 6.3 272 483 331(22), 313(21), 271(100), 211(16), 169(5) Digalloyl-glucoside(A) 15.7 ± 0.5 11.7 ± 0.2 <0.001
3 7.2 328 353 191(100), 179(32), 161(5), 135(5) 5-O-Caffeoylquinic acid(B) 22.5 ± 0.1 18.5 ± 0.8 <0.001
4 9.4 277 635 483(14), 465(100), 313(16), 211(5), 169(3) Trigalloyl-glucoside(A) 9.33 ± 0.03 7.1 ± 0.3 <0.001
5 11.0 340 493 317(100) Myricetin-O-glucuronide(C) 5.4 ± 0.7 4.62 ± 0.08 0.052
6 11.7 277 635 483(100), 465(9), 331(5), 313(7), 271(5), 211(5), 169(3) Trigalloyl-glucoside(A) 6.7 ± 0.3 5.47 ± 0.03 <0.001
7 12.5 278 635 483(100), 465(41), 313(14), 211(6), 169(3) Trigalloyl-glucoside(A) 6.3 ± 0.2 5.4 ± 0.1 0.001
8 13.2 253, sh360 463 301(100) Ellagic acid glucoside(D) 18.5 ± 0.2 19.0 ± 0.4 0.044
9 14.5 276 787 635(22), 617(27), 483(80), 465(100), 447(20),
423(78), 313(13), 271(8), 169(5)
Tetragalloyl-glucose(A) 3.1 ± 0.1 2.3 ± 0.1 <0.001
10 15.4 277 787 635(27), 617(22), 483(58), 465(100), 447(52),
423(19), 313(7), 271(5), 169(3)
Tetragalloyl-glucose(A) 5.3 ± 0.1 3.1 ± 0.1 <0.001
11 18.2 355 477 301(100) Quercetin-3-O-glucuronide(B) 4.95 ± 0.03 4.1 ± 0.1 <0.001
12 18.5 350 463 301(100) Quercetin-3-O-glucoside(B) 4.19 ± 0.04 4.48 ± 0.05 <0.001
13 18.6 283 497 313(55), 169(100) Eucaglobulin/Globulusin B(A) 17.69 ± 0.05 19.2 ± 0.8 0.011
14 21.4 354 433 301(100) Quercetin-O-pentoside(B) 1.31 ± 0.03 1.33 ± 0.01 0.149
15 22.5 354 447 301(100) Quercetin-O-rhamnoside(B) 2.7 ± 0.1 2.80 ± 0.03 0.306
16 23.3 358 461 315(100) Isorhametin-O-rhamnoside(B) 1.77 ± 0.04 1.82 ± 0.04 0.093
17 24.2 250, sh364 447 315(100), 301(38) Methylellagic acid pentoside(D) 2.94 ± 0.01 3.0 ± 0.1 0.186
18 33.5 355 547 463(67), 301(100) Quercetin derivative(B) 1.18 ± 0.01 1.16 ± 0.02 0.073
Total phenolic acids 43.91 ± 0.05 41 ± 1 0.002
Total gallotannins 92.0 ± 0.4 77 ± 1 <0.001
Total flavonoids 21.5 ± 0.5 20.3 ± 0.1 0.004
Total phenolic compounds 157.4 ± 0.2 138 ± 3 <0.001
Standard calibration curves: A – gallic acid (y = 131538x + 292163; R2 = 0.997); B – 5-O-caffeoylquinic acid (y = 168823x − 161172; R2 = 0.999); C – quercetin-3-O-glucoside (y = 34843x −

























































































Moreover, in order to verify whether the E. globulus decoc-
tion extract is also able to cause programmed cell death in
NCI-H460 cells, we have performed the Annexin V-FITC/PI
assay by flow cytometry. Interestingly, the treatment of
NCI-H460 cells with either the GI50 or 2 × GI50 concentrations
of the E. globulus decoction extract only caused a very modest
increase (not statistically significant) in the % of apoptotic
cells (GI50: 5%, 2 × GI50: 8%), when compared to the Blank
condition (data not shown). Altogether, these findings indicate
that the decoction extract of E. globulus may limit the growth
of NCI-H460 cells mainly by interfering with the cell cycle in
the G0/G1 and S phases, rather than by causing cellular
apoptosis.
E. globulus decoction extract decreased NCI-H460 cellular
proliferation
Given the alterations in the NCI-H460 cell cycle, we have
further investigated its repercussion on cell proliferation, by
analyzing the levels of BrdU incorporation following 48 h treat-
ment (Fig. 4a and b). Concordantly with the cell cycle profile
data, we have observed a decrease (although not statistically
significant) in the percentage of proliferating cells treated with
the 2 × GI50 concentration of the E. globulus extract, in relation
to the Blank control.
E. globulus decoction extract altered the NCI-H460 cell
expression levels of cell cycle-related proteins
Considering the previous results, we have further confirmed
the effect of the E. globulus decoction extract on the NCI-H460
cell cycle profile and apoptosis, by assessing the expression
Table 2 GI50 concentrations of E. globulus extracts in three distinct
human tumor cell lines
Extracts
GI50 concentrations (µg mL
−1) in different cell lines
PANC-1 HCT-15 NCI-H460
Infusion 70.4 ± 6.0 109.7 ± 17.2 68.0 ± 4.6
Decoction 74.0 ± 8.5 117.0 ± 22.5 51.7 ± 2.0
GI50 concentrations, determined with the SRB assay, correspond to the
mean ± S.E.M. of at least three independent experiments. Doxorubicin
(311.6 ± 26.5 nM in HCT-15 cells and 17.0 ± 2.0 nM in NCI-H460 cells)
and Gemcitabine (0.9 ± 0.2 µM in PANC-1 cells) GI50 concentrations
were used as positive controls.
Fig. 1 Dose–response curves of E. globulus infusion and decoction
extract treatments on PANC-1, HCT-15 and NCI-H460 tumor cells. The
results were determined with the SRB assay following 48 h incubation
with the extracts. Five concentrations of the extracts were tested,
ranging from 200 μg mL−1 to 12.5 μg mL−1. The results are presented as
the percentage (%) of cell growth when compared to Blank cells. The
results are the mean ± S.E.M. of at least three independent experiments.
Fig. 2 Effect of the E. globulus decoction extract on the NCI-H460
viable cell number. The viable cell number was analyzed 48 h following
incubation with the complete medium (Blank), 52 µg mL−1 (GI50) or
104 µg mL−1 (2 × GI50) of the E. globulus decoction extract, or with the
corresponding vehicle concentrations alone (Controls I and II). The
results are presented in relation to the Blank and are the mean ± S.E.M.
of eight independent experiments. **p ≤ 0.01, Blank vs. Treatment.
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levels of a panel of the cell cycle and apoptotic-related proteins
by western blot.
Interestingly, we have observed an increased expression in
the NCI-H460 cell line levels of p53 upon treatment (Fig. 5a).
Indeed, cell treatment with the GI50 and 2 × GI50 concen-
trations of the extract caused nearly 4- and 12-fold increases in
the p53 levels, respectively, when compared to the Blank
control. Importantly, these findings are aligned with the
results obtained in the cell cycle analysis. Indeed, higher levels
of p53 expression may trigger alterations in the cell cycle
profile by causing an activation of p21, an inhibitor of the
cyclin-dependent kinase at the G1-checkpoint.38–41 A cyclin D1
protein is required for the cell cycle progression through the
G1 phase, during which it is synthesized and accumulated in
the nucleus, following degradation when the cell enters in the
S phase.42 Indeed, it has been shown that cells with increased
levels of p53 arrest in the G1 phase, characterized by the
accumulation of p21, which in turn induces cyclin D1 pro-
duction.43 Importantly, and consistently with this line of
thought, we also found an increase in the NCI-H460 levels of
both p21 (with a 3- and 7-fold increase for GI50 and 2 × GI50,
respectively) and cyclin D1 (for 2 × GI50, with a 4-fold increase)
upon treatment with the E. globulus decoction extract (Fig. 5a).
Therefore, the observed increased levels of both p21 and cyclin
D1 in NCI-H460 cells upon treatment with the E. globulus
decoction extract strongly support the hypothesis that the
E. globulus extract induces cell cycle arrest in G0/G1 via p53
activation.
Regarding cell apoptosis, the E. globulus extract treatment
did not alter the NCI-H460 cellular levels of total poly (ADP-
ribose) polymerase (PARP), whose reduction is associated with
cellular apoptosis44,45 (Fig. 5b). Importantly, this result is in
accordance with the previous Annexin V-FITC/PI results,
Fig. 3 Cell cycle distribution of NCI-H460 cells treated with the
E. globulus decoction extract, analyzed by flow cytometry. (a)
Representative histograms of the NCI-H460 cell cycle profile. (b)
Percentage of NCI-H460 cells in the different phases of the cell cycle.
The cell cycle profile was analyzed 48 h following incubation with the
complete medium (Blank), 52 µg mL−1 (GI50) or 104 µg mL
−1 (2 × GI50)
of the E. globulus decoction extract, or with the corresponding vehicle
concentrations alone (Controls I and II). The results are presented as the
mean ± S.E.M. of at least three independent experiments. *p ≤ 0.05,
Blank vs. Treatment.
Fig. 4 Effect of the E. globulus decoction extract on NCI-H460 cellular
proliferation. (a) Representative fluorescence microscopy images of
BrdU incorporation (green) and DAPI stained nuclei (blue). (b)
Percentage of BrdU-incorporating cells. The results are presented as the
mean ± S.E.M. of 3 independent experiments. **p ≤ 0.01, Blank vs.
Treatment. Amplification = 200×.
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showing that the E. globulus decoction extract does not have an
impact on NCI-H460 cell death, at least at the concentrations
tested.
We have then investigated whether the E. globulus treatment
was able to induce double-stranded DNA damage in NCI-H460
cells. For that, the levels of the γ-H2A·X protein – a molecular
marker of DNA double-strand breaks46 – were assessed.
Importantly, NCI-H460 cells treated with both concentrations
of the extract had no alteration in γ-H2A·X protein levels
(Fig. 5c). However, this apparent lack of ds-DNA damage in
NCI-H460 cells upon treatment does not exclude the possi-
bility that other forms of DNA damage may be present (for
instance single-strand DNA damage), which could also explain
the activation of p53 and consequent cell cycle arrest in the
G0/G1 phase with a slower NCI-H460 cell growth.47,48
Conclusions
Herein we demonstrated that the E. globulus aqueous extracts
prepared by two different procedures – decoction and infusion
– are able to hinder the cell growth of three different human
tumor cell lines. Both extracts are a rich source of phenolic
compounds, especially gallotannins, and in particular digal-
loyl-glucoside. Importantly, this anti-tumor effect was more
pronounced in the non-small cell lung cancer cell line,
NCI-H460, with the decoction formulation, which could be
related to its higher content in polyphenols. Mechanistically,
the E. globulus decoction extract seems to primarily impact the
NCI-H460 cell cycle profile, causing an increase in the popu-
lation of cells in the G0/G1 phase via activation of the p53
pathway, with a consequent decrease in cell proliferation
(observed as an S phase decrease and also a BrdU incorpor-
ation decrease). Interestingly, this extract does not seem to
cause ds-DNA damage and did not induce programmed cell
death.
To the best of our knowledge, we present one of the first
reports on the mechanism of action of the E. globulus extract
on the NCI-H460 cells. Therefore, this work underlines the
potential of the E. globulus decoction extract as a source of bio-
active compounds with anti-tumor activity.
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